Lercanidipine modified release

Drug Profile

Lercanidipine modified release

Alternative Names: Lercanidipine MR

Latest Information Update: 29 Aug 2015

Price : $50

At a glance

  • Originator Recordati
  • Developer Allergan
  • Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top